![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Recommends Daily Aspirin for Lynch Syndrome Patients to Reduce Risk of Colorectal Cancer
NICE Recommends Daily Aspirin for Lynch Syndrome Patients to Reduce Risk of Colorectal Cancer
![NICE-logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/NICE-logo.gif?t=1604717099&width=430)
August 6, 2019
The UK’s National Institute for Health and Care Excellence (NICE) issued draft guidance advising patients with Lynch syndrome (LS) to take aspirin daily for two years or more to reduce the chance of getting colorectal cancer.
“While there are risks associated with long-term aspirin use, the committee agreed that the benefits are likely to outweigh any potential harms,” said Paul Chrisp, director of NICE’s Centre for Guidelines.
An estimated 175,000 individuals in the UK have the inherited genetic condition — and many are unaware that they have it.
Upcoming Events
-
21Oct